Pharma Contract Manufacturers

Laurus Labs' share price hit a new high of ₹2,338.90, bouncing back 154% from its 52-week low of ₹917.95 touched on February 2, 2026.

Thus far in the calendar year 2026, Acutaas Chemicals' market price has zoomed 116% compared to a 9.4% decline in the Nifty 500 index.

Laurus Labs Q2 outlook: On the EBITDA front, analysts at Kotak Institutional Equities build in 67% YoY growth to ₹680 crore in Q2FY27 with EBITDA margin expansion of 680 bps to 31.2%.

Kopran share price: Average volumes on the counter more than doubled with a combined 13.12 million shares having changed hands on BSE and NSE.

Morepen Laboratories' share price hit a multi-year high of ₹112.85, soaring 8 per cent on the BSE in Wednesday's intra-day trade.

In the past month, Sai Life Science stock surged 19 per cent, against a 2.8 per cent decline in the BSE Sensex.

India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.

Laurus Labs quoted higher for the fourth straight day, surging 15% in this period after delivering record quarterly revenue with expanded profitability and continued portfolio transformation.

The stock price of Laurus Labs hit a new high of ₹1,662.45 in intra-day deals on Monday; the stock has zoomed 176% in the past 14 months from levels of ₹601.75 on May 27, 2025.

Share price of Aether Industries hit a new high of ₹1,507.20, soaring 7% on the BSE in Thursday's intra-day trade.

Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.

The company's management said improved capacity utilisation, expansion in global markets, and contribution from newly launched products supported growth during the financial year 2025-26.

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.

Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

The company will continue to derive strength from the existence of experienced promoters and positive outlook for the GLP1 segment, which is expected to yield revenue to the company from FY27 onwards.

In the past one month, the stock price of pharmaceuticals company has gained 15 per cent, as compared to 11 per cent decline in the BSE Sensex.

Motilal Oswal remains positive on Laurus due to its strengthening position in gaining CDMO contracts, the addition of a growth lever in the generics space, and a steady ARV business.